Biocon Limited

Biocon Biologics Receives Japan MHLW Approval for Pegfilgrastim Biosimilar Marketing

Biocon Biologics receives Japan MHLW marketing approval for its Pegfilgrastim biosimilar. This oncology product strengthens Biocon's ₹17,321 Cr TTM revenue base.

Biocon · 25 Aug 2026, 8:29 AM IST